Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. China
  4. Shanghai Stock Exchange
  5. Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
  6. News
  7. Summary
    600196   CNE000000X38

SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.

(600196)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Fosun Pharma Leads Hong Kong Healthcare Stocks Higher on Vaccine Optimism

05/09/2021 | 11:52pm EDT

By Justina Lee

Healthcare stocks are trading higher in Hong Kong, led by Shanghai Fosun Pharmaceutical (Group) Co., after it announced a joint venture with German biotechnology company BioNTech SE to manufacture and sell coronavirus vaccines.

Shares of Shanghai-based Fosun Pharma rose as much as 23% to 61.35 Hong Kong dollars Monday morning, nearing a record, after the company said on Sunday it will have a plant in China capable of producing up to a billion doses annually of BioNTech's Covid-19 vaccine.

Fosun Pharma's shares were recently trading 17% higher at HK$58.50, bringing its year-to-date gains to 58%.

Gains by the stock and other Hong Kong-listed healthcare shares helped the Hang Seng Healthcare Index rise 2.7%. The broader Hang Seng Index was down 0.4%.

Sinopharm Group Co. advanced 6.4%, after the World Health Organization on Friday approved the company's Covid-19 vaccine for emergency use. CanSino Biologics Inc. added 6.1%. Wuxi Biologics (Cayman) Inc., which on Friday said it completed the acquisition of manufacturing facilities in China and Germany, gained 2.7%.

The sector's rise comes amid a resurgence of Covid-19 cases world-wide, with pharmaceutical companies and governments racing to supply sufficient vaccine doses as the coronavirus continues to mutate. Brokerage IG noted that India's Covid-19 cases aren't showing signs of peaking, which would build the case for a nationwide lockdown.

Write to Justina Lee at justina.lee@wsj.com

(END) Dow Jones Newswires

05-09-21 2351ET

Stocks mentioned in the article
ChangeLast1st jan.
BIONTECH SE -0.06% 313.26 Delayed Quote.284.51%
CANSINO BIOLOGICS INC. 6.58% 311 End-of-day quote.76.20%
DJ INDUSTRIAL 0.51% 35108.23 Delayed Quote.14.55%
HANG SENG 3.37% 26282.44 Real-time Quote.-6.63%
SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD. 6.25% 74.75 End-of-day quote.38.45%
SINOPHARM GROUP CO., LTD. 0.00% 20.75 End-of-day quote.10.02%
WUXI BIOLOGICS (CAYMAN) INC. 4.62% 124.6 End-of-day quote.21.21%
All news about SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
07/28SHANGHAI FOSUN PHARMACEUTICAL : An announcement has just been published by the i..
PU
07/19Sisram Medical Seeks $80 Million in Private Placement; Shares Fall 6%
MT
07/19SHANGHAI FOSUN PHARMACEUTICAL : Voluntary announcement entering into the placing..
PU
07/19SHANGHAI FOSUN PHARMACEUTICAL (GROUP : Ex-dividend day for final dividend
FA
07/14SINOVAC BIOTECH : Fosun-BioNTech COVID-19 vaccine completes China regulator revi..
RE
07/14MARKET CHATTER : BioNTech's COVID-19 Vaccine Advances to Administration Review i..
MT
07/14SHANGHAI FOSUN PHARMACEUTICAL : Poll results of the resolution proposed at the 2..
PU
07/13Hong Kong says no personal data shared in vaccine deal with Fosun
RE
07/13Sisram Medical Limited completed the acquisition of Shanghai Foshion Medical ..
CI
07/12Politics, health collided in Taiwan's tortured BioNTech vaccine talks
RE
More news
Financials
Sales 2021 40 257 M 6 235 M 6 235 M
Net income 2021 4 253 M 659 M 659 M
Net Debt 2021 15 917 M 2 465 M 2 465 M
P/E ratio 2021 44,1x
Yield 2021 0,70%
Capitalization 181 B 28 023 M 28 023 M
EV / Sales 2021 4,89x
EV / Sales 2022 4,33x
Nbr of Employees 32 258
Free-Float 58,8%
Chart SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
Duration : Period :
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Technical Analysis Chart | 600196 | CNE000000X38 | MarketScreener
Technical analysis trends SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Last Close Price 74,75 CNY
Average target price 57,08 CNY
Spread / Average Target -23,6%
EPS Revisions
Managers and Directors
Xiao Hui Guan Executive President & Chief Financial Officer
Yu Qing Chen Co-President
Ke Xin Wang Co-President
Dong Ming Li Co-President
Yi Fang Wu Chairman